Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-16-109553
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-18 18:04:39
Reporting Period:
2016-03-16
Filing Date:
2016-03-18
Accepted Time:
2016-03-18 18:04:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1245104 Globeimmune Inc GBIM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1113661 J Daniel Mitchell C/o Sequel Limited Partnership
4430 Arapahoe Ave, Ste 220
Boulder CO 80303
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-03-16 8,862 $1.85 78,426 No 4 S Indirect By Sequel Limited Partnership III
Common Stock Disposition 2016-03-16 112 $1.85 994 No 4 S Indirect By Sequel Entrepreneurs Fund III, LP
Common Stock Disposition 2016-03-17 12,468 $1.52 65,958 No 4 S Indirect By Sequel Limited Partnership III
Common Stock Disposition 2016-03-17 158 $1.52 836 No 4 S Indirect By Sequel Entrepreneurs Fund III, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Sequel Limited Partnership III
No 4 S Indirect By Sequel Entrepreneurs Fund III, LP
No 4 S Indirect By Sequel Limited Partnership III
No 4 S Indirect By Sequel Entrepreneurs Fund III, LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,000 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote to this Form 4.
  2. The general partner of the Sequel Limited Partnership III and Sequel Entrepreneurs Fund III, L.P. (collectively, the "Sequel Funds") is Sequel Venture Partners III, L.L.C. ("SVP III"). SVP III may be deemed to indirectly beneficially own the shares owned by the Sequel Funds. The Reporting Person is a manager of SVP III and may be deemed to be the indirect beneficial owner of the shares owned by the Sequel Funds. The Reporting Person disclaims beneficial ownership of the shares held by the Sequel Funds, except to the extent of his pecuniary interest arising therein.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote to this Form 4.